NRX invested $27 million in its subsidiary HOPE therapeutics to fund a nationwide rollup of Interventional Psychiatry Clinics. The agreement includes an immediate $2 million investment with a ...

Shares of NRx Pharmaceuticals stock opened at $3.14 on Tuesday. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $7.33. The stock has a market cap of $37.96 million, a P/E ...

NRx Pharmaceuticals (NRXP) announced that it has entered into a binding agreement for a registered direct offering of its common stock with expected gross proceeds of $3.5M with certain ...

Hope Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced engagement of BTIG, a leading global financial services ...

On January 15, 2025, NRx Pharmaceuticals, Inc. appointed Mike Taylor as a Class I member of its Board of Directors. Taylor, aged 50, brings with him 25 years of experience in the global credit ...

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE ...

The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for ...